{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:08:27Z","timestamp":1765296507567,"version":"3.46.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.1182\/bloodadvances.2025017109","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:10:31Z","timestamp":1757362231000},"page":"6042-6046","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8103-0326","authenticated-orcid":false,"given":"Ellinor","family":"Goergen","sequence":"first","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-6655","authenticated-orcid":false,"given":"Sandra","family":"Robrecht","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-0911","authenticated-orcid":false,"given":"Rudy","family":"Ligtvoet","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-0304","authenticated-orcid":false,"given":"Petra","family":"Langerbeins","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-4455","authenticated-orcid":false,"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"6","key":"2025120910512722500_bib1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025120910512722500_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"2025120910512722500_bib3","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"2025120910512722500_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/10428194.2024.2333448","article-title":"The prognostic significance of genomic complexity in patients with CLL","volume":"65","author":"Goergen","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025120910512722500_bib5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2021013208","article-title":"Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia","volume":"139","author":"Huber","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025120910512722500_bib6","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"issue":"17","key":"2025120910512722500_bib7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025120910512722500_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"10232","key":"2025120910512722500_bib9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"2025120910512722500_bib10","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"issue":"29","key":"2025120910512722500_bib11","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025120910512722500_bib12","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2025120910512722500_bib13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.2023019634","article-title":"High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations","volume":"142","author":"Furstenau","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025120910512722500_bib14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-022-01629-7","article-title":"Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial","volume":"36","author":"von Tresckow","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2025120910512722500_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.2020010484","article-title":"Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and\/or mutations","volume":"138","author":"Cramer","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2025120910512722500_bib16","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2025120910512722500_bib17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120910512722500_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/fon-2017-0442","article-title":"CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia","volume":"14","author":"Cramer","year":"2018","journal-title":"Future Oncol"},{"issue":"31","key":"2025120910512722500_bib19","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025120910512722500_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025120910512722500_bib21","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1080\/10428194.2022.2098291","article-title":"Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL","volume":"63","author":"Wierda","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2025120910512722500_bib22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"Furstenau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120910512722500_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2025120910512722500_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"34","key":"2025120910512722500_bib25","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6042\/2423723\/blooda_adv-2025-017109-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6042\/2423723\/blooda_adv-2025-017109-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:51:36Z","timestamp":1765295496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/6042\/547166\/Efficacy-of-MRD-triggered-anti-CD20-retreatment-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":25,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017109","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,11,26]]}}}